Alzheimer's disease & dementia

Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug

A new Alzheimer's drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns.

Diseases, Conditions, Syndromes

Doctors: Execution drugs could help COVID-19 patients

Secrecy surrounding executions could hinder efforts by a group of medical professionals who are asking the nation's death penalty states for medications used in lethal injections so that they can go to coronavirus patients ...

Diseases, Conditions, Syndromes

Cluster of coronavirus cases is tied to US biotech meeting

A biotech meeting at a hotel in downtown Boston appears to be the source of a cluster of the coronavirus in the U.S.—and a warning for employers who are still holding big gatherings as the outbreak spreads.

Medications

Industry executives: Profits drive rising prices for MS drugs

U.S. Medicare patients with multiple sclerosis often pay, on average, nearly $7,000 out of pocket to treat their condition each year. And, even though drug companies have provided no new treatment breakthroughs, the price ...

page 1 from 3